Original articleMycophenolate Mofetil for Ocular Inflammation
Section snippets
Study Population
All patients with noninfectious ocular inflammatory disease who had started receiving treatment with mycophenolate mofetil during the study as the sole noncorticosteroid immunosuppressive agent at 3 ocular immunology and uveitis clinics and an approximate 40% random sample of such patients from a fourth center were selected to be the study population. This group of patients was nested within a larger study, the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study, the methods
Results
During follow-up, 236 patients started mycophenolate mofetil as a single (noncorticosteroid) immunosuppressive treatment. Their characteristics at the time when mycophenolate mofetil was started are given in Table 1. The median age was 47.1 years (range, 8.1–84.2 years); 64% were female and 67% were Caucasian. The mean duration of inflammation prior to starting mycophenolate mofetil was 3 years. Bilateral involvement was present in 68% of patients; 130 patients (32.7%) had a visual acuity of
Discussion
The effectiveness of mycophenolate mofetil for ocular inflammation has been reported in 3 prior medium-sized cohort reports,11, 12, 14 which differed from our methodology by including patients on combination immunosuppression in their series, and by not requiring that control of inflammation be sustained before counting a patient as achieving corticosteroid-sparing success. Among 73 patients who received mycophenolate mofetil as therapy for ocular inflammation, corticosteroid-sparing success
References (27)
- et al.
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
Am J Ophthalmol
(2000) - et al.
Characterization of human type I and type II INP dehydrogenases
J Biol Chem
(1993) - et al.
Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation
Ophthalmology
(2008) - et al.
Mycophenolate mofetil therapy for inflammatory eye disease
Ophthalmology
(2005) - et al.
Mycophenolate mofetil-induced neutropenia in liver transplantation
Transplant Proc
(2005) The natural history of uveitis
Int Ophthalmol
(1990)- et al.
Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation
Clin Experiment Ophthalmol
(2005) - et al.
Mycophenolate mofetil in the treatment of uveitis in children
Br J Ophthalmol
(2007) - et al.
Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitisA retrospective analysis of 106 patients
Graefes Arch Clin Exp Ophthalmol
(2006) - et al.
MMF and eye disease
Lupus
(2005)
Mechanisms of action of mycophenolate mofetil
Lupus
Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability
Ann N Y Acad Sci
Use of mycophenolate mofetil in autoimmune and renal diseases
Transplantation
Cited by (211)
Immunomodulatory Treatment Versus Systemic Steroids in Inflammatory Choroidal Neovascularization Secondary to Idiopathic Multifocal Choroiditis
2024, American Journal of OphthalmologyPunctate inner choroidopathy: A review of the current diagnostic and therapeutic approaches
2024, Progress in Retinal and Eye ResearchThe Humira in Ocular Inflammations Taper (HOT) Study
2024, American Journal of OphthalmologyScleritis and episcleritis
2023, Revue de Medecine InterneResponse to Acthar Gel in sarcoidosis uveitis: A prospective open label study
2023, Respiratory MedicineClinical Pharmacology in Sarcoidosis: How to Use and Monitor Sarcoidosis Medications
2024, Journal of Clinical Medicine
Supplemental Material available at AJO.com.